瑞舒伐他汀对急性冠脉综合征患者血同型半胱氨酸水平的影响

Effects of Rosuvastatain on Homocysteine in Patients with Acute Coronary Syndrome

目的观察不同剂量瑞舒伐他汀对急性冠脉综合征(ACS)患者同型半胱氨酸(Hcy)水平的影响。方法选取我院150例ACS住院患者,随机分为3组。在常规治疗基础上,A组予瑞舒伐他汀5mg,每晚1次顿服;B组瑞舒伐他汀10mg,每晚1次顿服;C组予辛伐他汀20mg,每晚1次顿服。分别于服药前及服药第4周、8周抽血检测血Hcy水平。结果治疗前3组患者间血Hcy水平差异无统计学意义(P>0.05)。治疗4周后A组、C组患者血Hcy水平较治疗前略下降(P>0.05),B组患者较治疗前明显下降(P<0.05)。治疗8周后,3组患者Hcy水平较治疗前均明显下降(P<0.05),B组较A组、C组患者下降更明显(P<0.05)。结论 10mg/d瑞舒伐他汀降低ACS患者血Hcy的效果更明显,从而提示此剂量瑞舒伐他汀可以更有效地预防ACS的发生。

Objective To observe effects of rosuvastatain on homocysteine in patients with acute coronary syndrome. Methods One hundred and fifty patients with acute coronary syndrome were randomly divided into three groups：A group（rosuvastatain,5 mg/d）,B group （ rosuvastatain, 10 mg/d）, and C groups （ simvastatin, 20 rag/d）. Total cholesterol, glycerin, high density lipoprotein cholesterol, low density lipoprotein cholesterol, and homocysteine （Hcy） were tested and compared. Results There were no significant difference in the level of Hcy in three groups （P〉0.05）. After treatment for 4 weeks,Hcy in A and C groups was lower than that before treat- ment slightly（P〉0.05）. After treatment for 4 weeks, Hcy in B groups was lower than that before treatment （P〈0.05）. After treat- ment for 8 weeks, Hcy in three groups was lower than before treatment （P〈0.05）. After treatment for 8 weeks, Hcy in B groups was lower compare to that in A and C groups（P〈0.05）. The incidences of liver damage were no significant difference in three groups. Conclusion Effects of 10 mg/d rosuvastatain were better than 5 mg/d rosuvastatain and 20 mg/d simvastatin on Hcy in pa- tients with acute coronary syndrome. This dose rosuvastatain could effectively control morbidity of ACS.